Flamel Technologies SA (NASDAQ:FLML)’s share price was up 3.3% during trading on Thursday . The stock traded as high as $12.66 and last traded at $12.36, with a volume of 137,118 shares trading hands. The stock had previously closed at $11.96.

Several equities analysts have commented on FLML shares. Leerink Swann reiterated a “buy” rating and issued a $16.00 target price on shares of Flamel Technologies SA in a research report on Tuesday, May 10th. Zacks Investment Research upgraded Flamel Technologies SA from a “sell” rating to a “hold” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $18.63.

The stock has a 50-day moving average of $10.58 and a 200 day moving average of $10.48. The stock has a market cap of $512.63 million and a price-to-earnings ratio of 23.54.

Flamel Technologies SA (NASDAQ:FLML) last issued its quarterly earnings results on Monday, May 9th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by $0.10. The business earned $36.20 million during the quarter, compared to analysts’ expectations of $34 million. Flamel Technologies SA’s revenue for the quarter was up 10.7% on a year-over-year basis. Equities research analysts expect that Flamel Technologies SA will post ($0.03) EPS for the current year.

In other news, CEO Michael S. Anderson purchased 5,000 shares of the company’s stock in a transaction on Thursday, May 12th. The stock was purchased at an average price of $8.84 per share, with a total value of $44,200.00. Following the completion of the purchase, the chief executive officer now directly owns 134,250 shares in the company, valued at approximately $1,186,770. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Craig R. Stapleton purchased 27,228 shares of the company’s stock in a transaction on Monday, May 16th. The shares were purchased at an average cost of $9.21 per share, with a total value of $250,769.88. Following the purchase, the director now owns 507,263 shares of the company’s stock, valued at $4,671,892.23. The disclosure for this purchase can be found here.

Other large investors have recently modified their holdings of the company. Turner Investments L.P. raised its stake in shares of Flamel Technologies SA by 77.3% in the fourth quarter. Turner Investments L.P. now owns 239,308 shares of the company’s stock valued at $2,922,000 after buying an additional 104,340 shares during the period. Morgan Stanley raised its stake in shares of Flamel Technologies SA by 131.4% in the fourth quarter. Morgan Stanley now owns 719,463 shares of the company’s stock valued at $8,785,000 after buying an additional 408,531 shares during the period. Tekla Capital Management LLC purchased a new stake in shares of Flamel Technologies SA during the fourth quarter valued at about $5,791,000. Heartland Advisors Inc. purchased a new stake in shares of Flamel Technologies SA during the fourth quarter valued at about $3,053,000. Finally, Sei Investments Co. purchased a new stake in shares of Flamel Technologies SA during the fourth quarter valued at about $2,129,000.

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.